Giorgio V. Scagliotti

Ospedale San Luigi Gonzaga — Italy

Medicine · Health Sciences

92h-index50.4kcitations1.0kworks1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(517), Lung Cancer Research Studies(297), Colorectal Cancer Treatments and Studies(159), Lung Cancer Diagnosis and Treatment(158), Cancer Immunotherapy and Biomarkers(141)

Publications1.0k total

Supplementary Figure S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S8 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S3 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S4 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S9 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S7 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S10 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S6 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Table S5 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC
2025Open Access
Supplementary Figure S4 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S13 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S10 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
2025Open Access
Supplementary Figure S2 from Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
2025Open Access
page 1 of 52Next →

Frequent Co-authors

Silvia Novello(12), Joachim von Pawel(8), Rafael Rosell(8), Fred R. Hirsch(7), Christian Manegold(7), Filippo de Marinis(7), Frances A. Shepherd(7), Lucio Crinò(6), Johan Vansteenkiste(5), David R. Gandara(5), Tony Mok(5), Ignacio I. Wistuba(4), Ming‐Sound Tsao(4), U. Gatzemeier(4), Lorinda Simms(4), Katherine P. Sugarman(4), Valter Torri(4), Thierry Le Chevalier(4), Roy S. Herbst(4), Lynette M. Sholl(4)